SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

26 дек 2023 10:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

20 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing

19 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.

15 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population

12 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State

06 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee

04 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Available Information

01 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan

30 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.

28 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024

27 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy

22 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB®

21 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch

17 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch

15 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders

02 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)

02 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information

01 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure

27 окт 2023 14:38:47 Источник Nasdaq GlobeNewswire

Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure

27 окт 2023 13:05:41 Источник Nasdaq GlobeNewswire